img
img
Jorge Conde
Bio + Health

Jorge Conde

Investing

More About Jorge

Jorge Conde is a General Partner on the Bio + Health team, where he focuses on life sciences and healthcare investments across therapeutics, diagnostics, tools, and software. Jorge currently serves on the boards of Asimov, CAMP4, Cartography, Doppler Bio, Dyno, Earli, IDRx, Komodo Health, Octant Bio, Tome Biosciences, and Vicinitas.

Prior to joining Andreessen Horowitz, Jorge served as Chief Strategy Officer, Chief Financial Officer, and Chief Product Officer for Syros. Jorge was also cofounder and Chief Executive Officer of Knome, a human genome interpretation company acquired by Tute Genomics in 2015. Before that, Jorge worked in marketing and operations at MedImmune and as a biotechnology investment banker at Morgan Stanley.

Jorge holds an MBA from Harvard Business School, an MS from the Harvard-MIT Division of Health Sciences and Technology, and a BA in biology from Johns Hopkins University. Jorge was named one of the top 35 young innovators in the world by the MIT Technology Review and is a Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. He previously served on the board of the Museum of Science, Boston.

Born and raised in Miami by Cuban and Peruvian parents, and married to a Madrileña, Jorge and his family of six live in California. The family cheers for Real Madrid, the Boston Red Sox, and the Miami Dolphins.

Latest Content

  • Drag & Drop Genome Editing
    Jorge Conde, John Finn, Rahul Kakkar, Kris Tatiossian, and Olivia Webb

    Today's episode features the cofounders of Tome Biosciences, Rahul Kakkar, CEO of Tome, and John Finn, CSO. They are joined by Jorge Conde, general partner at a16z Bio + Health.

  • The New Drug Delivery Challenge: How Will Cures Reach Patients?
    Jay Rughani, Annie Collins, Jorge Conde, and Julie Yoo

    All this to say—it’s time to figure out how to access, pay for, and deliver curative therapies (amongst other high-cost, complex, specialty drugs), at scale. Let’s dive into the specific challenges that need to be surmounted to get this right.

  • Tome is launching with over $200 million to advance its PGI platform to focus on in vivo and ex vivo applications, with support from a16z Bio + Health, ARCH, GV, Longwood, Polaris and other leading investors. First up on Tome’s in vivo surgical slate: monogenic diseases of the liver. On the ex vivo cell engineering front, Tome is using PGI to rewire cells to cure common, chronic diseases—an area of great promise—with an initial focus on B-cell driven autoimmune diseases.

  • 2024 Big Ideas: Miracle Drugs, Programmable Medicine, and AI Interpretability
    Julie Yoo, Jorge Conde, Anjney Midha, and Stephanie Smith

    Smart energy grids. Voice-first companion apps. Programmable medicines. AI tools for kids.
We asked over 40 partners across a16z to preview one big idea they believe will drive innovation in 2024. Here in our 3-part series, you’ll hear directly from partners across all our verticals, as we dive even more deeply into these ideas. What’s the why now? Who is already building in these spaces? What opportunities and challenges are on the horizon? And how can you get involved?

  • Today’s landmark approval by the US Food and Drug Administration of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ EXA-cell, the world’s first CRISPR-based treatment, marks a groundbreaking shift in how we tackle intractable diseases.

Load More

Select Investments

Any investments or portfolio companies mentioned, referred to, or described on this page are not representative of all investments. A list of investments made by funds managed by a16z is available here: https://a16z.com/investment-list/.

go to top